What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Jaffer A. Ajani mostly deals with Internal medicine, Surgery, Cancer, Chemotherapy and Adenocarcinoma.
His studies deal with areas such as Gastroenterology and Oncology as well as Internal medicine.
His Surgery study which covers Clinical trial that intersects with Adjuvant therapy.
He combines subjects such as Cancer research, General surgery and Pathology with his study of Cancer.
His Chemotherapy research incorporates elements of Vomiting and Dissection.
His work in Adenocarcinoma addresses subjects such as Bioinformatics, which are connected to disciplines such as Gene expression profiling and Transcriptome.
His most cited work include:
- Comprehensive molecular characterization of gastric adenocarcinoma (2822 citations)
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction (2676 citations)
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group (1446 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Cancer, Oncology, Surgery and Gastroenterology.
The Chemotherapy, Esophageal cancer, Adenocarcinoma and Carcinoma research Jaffer A. Ajani does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His work carried out in the field of Cancer brings together such families of science as Stage, Cancer research, Hazard ratio and Pathology.
Jaffer A. Ajani interconnects Clinical trial, Disease, Cisplatin and Docetaxel in the investigation of issues within Oncology.
His Surgery research focuses on Radiation therapy, Chemoradiotherapy, Survival rate, Fluorouracil and Phases of clinical research.
His Gastroenterology research includes elements of Neutropenia, Toxicity and Confidence interval.
He most often published in these fields:
- Internal medicine (54.61%)
- Cancer (37.83%)
- Oncology (32.49%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (54.61%)
- Cancer (37.83%)
- Oncology (32.49%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Cancer, Oncology, Cancer research and Gastroenterology.
His study on Chemotherapy, Adenocarcinoma, Esophageal cancer and Hazard ratio is often connected to In patient as part of broader study in Internal medicine.
His Cancer study combines topics in areas such as Stage, Surgical oncology and Surgery.
Jaffer A. Ajani works on Surgery which deals in particular with Retrospective cohort study.
The various areas that Jaffer A. Ajani examines in his Oncology study include Gastroesophageal adenocarcinoma, Nivolumab and Radiation therapy.
The concepts of his Gastroenterology study are interwoven with issues in Gastric adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Confidence interval, Placebo and Proportional hazards model.
Between 2016 and 2021, his most popular works were:
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy (296 citations)
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (198 citations)
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study (165 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Jaffer A. Ajani spends much of his time researching Cancer, Internal medicine, Oncology, Cancer research and Esophageal cancer.
He has researched Cancer in several fields, including Surgery, Surgical oncology and Proportional hazards model.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His Oncology research is multidisciplinary, incorporating perspectives in Clinical trial, Phases of clinical research, Radiation therapy and Cohort.
His Esophageal cancer research also works with subjects such as
- Chemoradiotherapy which intersects with area such as Neoadjuvant therapy,
- Radiology which connect with Odds ratio.
His research in Adenocarcinoma intersects with topics in Esophagectomy, Carcinoma, Pathology, Esophagus and Endoscopic ultrasound.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
